RT Journal Article SR Electronic T1 Role of β-lactamases and efflux pumps in multidrug resistance in Pseudomonas aeruginosa isolated from patients in the Intensive Care Unit in the northeast of Brazil JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.04.23.24306233 DO 10.1101/2024.04.23.24306233 A1 Maia, Marília S. A1 Nogueira, Lavouisier F.B. A1 Clementino, Marco A.F A1 Filho, Jose Q.S. A1 Lima, Ila F.N. A1 Sousa, José K. A1 Costa, Deiziane V.S. A1 Rodrigues, Jorge L.N. A1 Fragoso, Luciana V.C. A1 Havt, Alexandre A1 Lima, Aldo A.M. YR 2024 UL http://medrxiv.org/content/early/2024/04/24/2024.04.23.24306233.abstract AB Pseudomonas aeruginosa is an opportunistic pathogen of great clinical relevance in intensive care units (ICU), mainly due to its high resistance to various antimicrobials, which sometimes makes effective treatment impossible, leading to high morbidity and mortality in patients in critical situations. In this study, we aimed to detect variants of genes encoding β-lactamases and efflux pumps in P. aeruginosa isolates resistant to β-lactams, fluoroquinolones and aminoglycosides. All genes belonging to the subfamilies were included in the study: blaSHV, blaTEM, blaNDM, blaKPC, blaGES, blaCTX-M. In addition, we investigate the most relevant variants of the blaOXA subfamily and genes belonging to the efflux pumps of the Mex family. We tested 54 isolates of P. aeruginosa, finding a high prevalence of phenotypic resistance to the antimicrobials piperacillin with tazobactam, ceftazidime, cefepime, imipenem and meropenem, with a high positivity in the presence of resistance genes related to carbapenems and spectrum β-lactamases extended, mainly for the blaKPC genes with 81.49%, followed by blaCTXM-2 with 72.22% and blaCTXM-1 with 66.66%. In relation to the presence of Mex family efflux pumps there was a rate of 100% of positivity. These results suggest that the P. aeruginosa strains isolated have an arsenal of genes encoding β-lactamases capable of inducing phenotypic patterns of resistance to several antimicrobials commonly used for these infections, making treatment difficult for the patients in this clinical ward.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by by CNPq (http://www.cnpq.br), grant numbers 402607/2018-0 and 408549/2022-0. And FUNCAP (https://www.funcap.ce.gov.br/), grant number: OFICIO no. 102/2021 - DINOV.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Brazilian National Research Ethics Commission gave ethical approval for this work. Approval number (no. 03300218.2.0000.5054).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data and reports relating to this study will be available via direct request via email to the corresponding author.